文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-PFPN PET:恶性黑色素瘤患者一种有吸引力的新型显像模式

18F-PFPN PET: A New and Attractive Imaging Modality for Patients with Malignant Melanoma.
PubMed 文献 · J Nucl Med · 2022-02-03

本研究先用5名健康志愿者评估18F-PFPN的分布、药代动力学、辐射剂量与安全性,再对21例临床疑似或确诊恶性黑色素瘤患者行18F-PFPN PET/MRI与18F-FDG PET/CT,比较病灶标准化SUVmax;结果显示18F-PFPN摄取在原发性肿瘤及淋巴结转移灶均高于18F-FDG,并能检出365个18F-FDG PET漏诊的转移灶。

要点

  • 18F-PFPN在健康志愿者中安全且耐受良好,有效吸收剂量与18F-FDG相当。
  • 在患者分析中,原发肿瘤和淋巴结转移灶的18F-PFPN摄取均高于18F-FDG。
  • 病灶分析中,18F-PFPN PET检出365个18F-FDG PET漏诊的转移灶。

核心结论

  • 18F-PFPN是一种安全且耐受良好的黑色素PET示踪剂。
  • 在一项先导性临床研究中,18F-PFPN PET在识别原发恶性黑色素瘤及其远处播散方面优于传统18F-FDG PET。

研究设计与样本

  • 18F-PFPN通过氟-对甲苯磺酸酯交换反应合成。
  • 纳入5名健康志愿者研究示踪剂的生物分布、药代动力学、辐射剂量学与安全性。
  • 共21例临床疑似或确诊恶性黑色素瘤患者接受18F-PFPN PET/MRI与18F-FDG PET/CT扫描。
  • 对选定病灶测定两种示踪剂的标准SUVmax,并进行基于患者和基于病灶的分析比较。

主要发现

  • 18F-PFPN放射化学产率较高且在体内高度稳定。
  • 健康志愿者中18F-PFPN安全且耐受良好,其有效吸收剂量与18F-FDG相当。
  • 基于患者分析中,原发肿瘤和淋巴结转移灶的18F-PFPN摄取均高于18F-FDG。
  • 基于病灶分析中,18F-PFPN PET检出365个18F-FDG PET漏诊的转移灶。
  • 18F-PFPN PET在区分18F-FDG PET假阳性病灶方面具有临床价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-FDG PET has limited diagnostic applications in malignant melanoma (MM). 18F-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide (18F-PFPN) is a novel PET probe with high affinity and selectivity for melanin. We conducted a clinical study with 2 aims, first to investigate the biodistribution and radiation dosimetry of 18F-PFPN in healthy volunteers, and second, to examine the diagnostic utility of 18F-PFPN PET imaging in patients with MM. Methods: 18F-PFPN was synthesized through a fluoro-for-tosyl exchange reaction. Five healthy volunteers were enrolled to investigate the biodistribution, pharmacokinetics, radiation dosimetry, and safety of the tracer. Subsequently, a total of 21 patients with clinically suspected or confirmed MM underwent both 18F-PFPN PET/MRI and 18F-FDG PET/CT scans. The normalized SUVmax of selected lesions was determined for both tracers and compared in patient- and lesion-based analyses. Results: 18F-PFPN has an elevated radiochemical yield and was highly stable in vivo. In healthy volunteers, 18F-PFPN was safe and well tolerated, and its effective absorbed dose was comparable to that of 18F-FDG. In patient-based analysis, 18F-PFPN uptake was higher than 18F-FDG for both primary tumors and nodal metastases. In lesion-based analysis,18F-PFPN PET imaging could detect 365 metastases that were missed on 18F-FDG PET. Additionally, 18F-PFPN PET imaging had clinical value in distinguishing false-positive lesions on 18F-FDG PET. Conclusion: 18F-PFPN is a safe and well-tolerated melanin PET tracer. In a pilot clinical study, 18F-PFPN PET imaging outperformed traditional 18F-FDG PET in identifying both primary MM and its distant spread.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang X, Li M, Gai Y, et al. 18F-PFPN PET: A New and Attractive Imaging Modality for Patients with Malignant Melanoma. J Nucl Med. 2022. PMID: 35115367. doi:10.2967/jnumed.121.263179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。